Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL)

portefeuille (99.81) Submitted: 12/15/2011 9:36:10 PM : Start Price: $13.90 AUXL Score: +22.90

There are currently 100 AUXL shares in my "fund" with break-even of around 18.86 USD.
http://caps.fool.com/Blogs/fund-trades/678775.

21popsontop (< 20) Submitted: 11/24/2010 5:39:07 AM : Start Price: $19.70 AUXL Score: -14.05

Drug dealers with a license.

zzlangerhans (99.23) Submitted: 5/27/2010 10:22:42 PM : Start Price: $28.99 AUXL Score: -55.06

Auxilium has been selling off lately likely due to pessimism about the launch of Xiaflex. Do I have an inside track on the issues of usage and reimbursement? Unfortunately not. But I don't believe the drop in share price indicates that anyone else does either. With Testim revenues still increasing and the jury still out on Xiaflex I believe the risk/reward profile has swung towards green.

Ikeydoc (< 20) Submitted: 7/4/2009 11:40:46 AM : Start Price: $29.95 AUXL Score: -87.36

Release of treatment for Dupuytrens Disease

greenwave3 (92.93) Submitted: 8/27/2008 12:18:19 AM : Start Price: $39.79 AUXL Score: +60.15

Nice products, too much hype. How can you justify a market cap of $1.6 Billion with sales of under $100 Million? Some claim 20% annual sales growth. Even assuming they're correct, this one needs to be chopped in half before we even start to think about a fair valuation.

bernies1 (28.25) Submitted: 3/24/2008 8:18:56 PM : Start Price: $26.47 AUXL Score: -30.00

good stock

supez2004 (52.37) Submitted: 3/3/2008 1:08:22 AM : Start Price: $32.04 AUXL Score: -44.72

Xiaflex has potential to be a blockbuster drug in a niche market without many competitors ...

datasource (< 20) Submitted: 2/25/2008 4:06:07 PM : Start Price: $33.22 AUXL Score: +44.10

Overepriced with negative earnings for the foreseable future.

Also is currently a one-product company with mixed results in the whole synthetic testosterone marketplace. There are negative stories in the print press regarding the effectiveness of such products, including at least one that suggests that treatments can have the opposite of the desired effect.

NVR2LATE4MONEY (< 20) Submitted: 12/6/2007 4:02:19 PM : Start Price: $28.25 AUXL Score: -24.24

Auxl has a hot pipeline

htbrennan (52.46) Submitted: 8/9/2007 12:03:28 PM : Start Price: $22.53 AUXL Score: -9.41

CEO is a marketer,Exec. VP, Medimmune, rather than a Doc. Already have product and in late stage with new, so marketing is important.

mblin13 (33.05) Submitted: 3/1/2007 12:57:53 PM : Start Price: $12.32 AUXL Score: +56.95

downside provided by testim;
other drugs in phase 3 trials;
stock could triple

hlacheen (98.91) Submitted: 2/14/2007 12:32:08 AM : Start Price: $14.54 AUXL Score: -35.52

Another crappy pharmaceutical company that will never earn a profit.